

January 20, 2023

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	--

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

Further to our intimation dated October 28, 2022, on the Pre-Approval Inspection (PAI) conducted by the United States Food & Drug Administration (USFDA) at our manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh from 24th October 2022 to 28th October 2022, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from USFDA.

This is for your information and record.

Yours faithfully,
For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary